Clinical TrialOct 9, 2026, 08:36 AM
Eupraxia Pharmaceuticals to Present EoE Trial Data at ACG and UEG Conferences
AI Summary
Eupraxia Pharmaceuticals Inc. announced that abstracts related to its ongoing Phase 1b/2 RESOLVE trial of EP-104GI for eosinophilic esophagitis (EoE) have been accepted for presentation at the American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) medical conferences. The presentations will cover data showing improvements in dysphagia and histopathological features persisting up to 52 weeks. The company also noted that interim data from the Phase 2b portion of the RESOLVE trial is expected in December 2026. Eupraxia is leveraging its proprietary Diffusphere™ technology for localized drug delivery.
Key Highlights
- Eupraxia Pharmaceuticals to present abstracts on EP-104GI for eosinophilic esophagitis at ACG and UEG conferences.
- Phase 1b/2 RESOLVE trial data shows improvements in dysphagia persisting over 52 weeks with EP-104GI.
- EP-104GI demonstrated improvements in histopathological features of eosinophilic esophagitis.
- Phase 2b portion of the RESOLVE trial is recruiting, with interim data expected in December 2026.
- Eosinophilic esophagitis affects over 450,000 people in the United States.
- Eupraxia's Diffusphere™ technology aims for optimized local, controlled drug delivery.
Price Impact
More from EPRX